Home > Inhibitors & Agonists > Metabolic Enzyme/Protease > Ser/Thr Protease
Cat. No. Product name CAS No.
DC46972 CRA-2059 hydrochloride

CRA-2059 hydrochloride is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ).

DC47166 CRA-2059 TFA

CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ).

DC47182 Tilpisertib

Tilpisertib is a serine/threonine kinase inhibitor (WO2017007689).

2065153-41-3
DC47292 Inclisiran

Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.

1639324-58-5
DC47297 SLN124

SLN124 is a GalNac-siRNA targeting transmembrane serine protease 6 (Tmprss6). SLN124 is composed of a trimeric GalNAc ligand conjugated to TMPRSS6‐siRNA. SLN124 has the potential for an siRNA to restore hepcidin expression and normalise iron homeostasis in β‐thalassaemia.

DC47337 PCSK9-IN-2

PCSK9-IN-2 is a novel small molecule inhibitor of PCSK9-LDLR protein–protein interaction (PPI) with an IC50 value of 7.57 μM.

2099167-44-7
DC47872 WNK-IN-11-d3

WNK-IN-11 D3 is an orally active, selective and potent With-No-Lysine (WNK) kinase inhibitor. WNK-IN-11 D3 is effective at regulating cardiovascular homeostasis.

2123483-49-6
DC47927 PCSK9-IN-3

PCSK9-IN-3 is a novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitor.

DC48248 PCSK9-IN-1

PCSK9-IN-1 is a novel and highly potent cyclic peptide PCSK9 inhibitor with a Ki value of 1.46 nM.

2730022-10-1
DC48249 APC-6860

APC-6860 is a trypsin-like serine proteases inhibitor with ki values of 0.21, 0.44, 1.5, 16.8, 20, 30 μM for uPA, trypsin, tryptase, tPA, thrombin and factor Xa, respectively. APC-6860 has a selectivity ratio for tPA versus uPA of 80. APC-6860 has ki values of 0.1, 0.082 μM for human and murine urokinases, respectively. APC-6860 can be used for the research of cancer.

154628-42-9
DC48438 Upamostat (WX-671)

Upamostat (WX-671), a novel serine protease urokinase (uPA) inhibitor by inhibiting the urokinase-type plasminogen activator (uPA) system.

590368-25-5
DC49801 Evolocumab

Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.

1256937-27-5
DC49802 APC 366

APC 366 is a selective inhibitor of mast cell tryptase (Ki=7.1 μM). APC 366 inhibits antigen-induced early asthmatic response (EAR), late asthmatic response (LAR), and bronchial hyperresponsiveness (BHR) in a sheep model of allergic asthma.

158921-85-8
DC49803 VD2173

VD2173 is a side chain cyclized macrocyclic peptide inhibitor of HGF-activating serine proteases. VD2173 potently inhibits matriptase and hepsin. VD2173 can be used for the research of lung cancer.

2574389-19-6
DC49804 ZK824190 hydrochloride

ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively.

2629177-12-2
Page 1 / Total 1 FirstPrevNextLastGoto